PMID- 18262045
OWN - NLM
STAT- MEDLINE
DCOM- 20080429
LR  - 20081121
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 181
IP  - 1
DP  - 2008 Feb
TI  - Molecular cytogenetic characterization of human breast cancer cell line 
      MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis.
PG  - 1-7
LID - 10.1016/j.cancergencyto.2007.05.030 [doi]
AB  - Two human breast carcinoma cell lines, MDA-MB-468 and its variant MDA-MB-468LN, 
      which displays aggressive lymphatic metastasis, were investigated for molecular 
      cytogenetic characteristics using G-banding, spectral karyotyping, and 
      fluorescence in situ hybridization (FISH). Both cell lines have multiple 
      chromosome aberrations, but differ in the types of rearrangements and their 
      breakpoints. The MDA-MB-468 karyotype identified in the present study differs 
      from that previously reported, which suggests that this cell line is unstable. 
      Neither cell line exhibited amplification of ERBB2 (alias HER-2) by FISH. 
      MDA-MB-468 cells have a modal number of 60, with 42 types of aberrations: 11 
      numerical and 31 structural. 468LN cells have a modal number of 55, with 37 types 
      of aberrations: 10 numerical and 27 structural. The most common aberrations in 
      MDA-MB-468 cells were der(5)t(5;16), i(7)(p10), i(18)(p10), der(19)t(2;19), 
      del(6)(q23), and der(10)t(1;10). The most common aberrations in 468LN cells were 
      der(18)t(10;18), +5, der(1;7)(q10;q10), der(19)t(2;18;19), and der(20)t(20;21). 
      This cytogenetic result is consistent with previous findings that showed 
      differences in tumorigenicity and metastatic capability of these two cell lines 
      and indicates that 468LN is a new cell line distinctive from MDA-MB-468. We 
      hypothesize that the cytogenetic changes in 468LN may be related to its new 
      biological characteristics. Knowledge of the chromosome aberrations and 
      breakpoints identified could be useful for further genetic and epigenetic studies 
      of breast cancer.
FAU - Xu, Jie
AU  - Xu J
AD  - Cytogenetics Laboratory, London Health Sciences Centre, University of Western 
      Ontario, 375 South Street, Room N258, London, Ontario N6A 4G5, Canada. 
      Jie.Xu@lhsc.on.ca
FAU - Chambers, Ann F
AU  - Chambers AF
FAU - Tuck, Alan B
AU  - Tuck AB
FAU - Rodenhiser, David I
AU  - Rodenhiser DI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 147336-22-9 (Green Fluorescent Proteins)
SB  - IM
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Cell Line, Tumor
MH  - Chromosome Aberrations
MH  - Female
MH  - Gene Rearrangement
MH  - Genetic Variation
MH  - Green Fluorescent Proteins/genetics
MH  - Humans
MH  - Lymphatic Metastasis/*pathology
MH  - Mutagenesis, Insertional
MH  - Sequence Deletion
MH  - Transfection
EDAT- 2008/02/12 09:00
MHDA- 2008/04/30 09:00
CRDT- 2008/02/12 09:00
PHST- 2007/02/12 00:00 [received]
PHST- 2007/05/04 00:00 [accepted]
PHST- 2008/02/12 09:00 [pubmed]
PHST- 2008/04/30 09:00 [medline]
PHST- 2008/02/12 09:00 [entrez]
AID - S0165-4608(07)00589-4 [pii]
AID - 10.1016/j.cancergencyto.2007.05.030 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2008 Feb;181(1):1-7. doi: 
      10.1016/j.cancergencyto.2007.05.030.